CJC-1295 No DAC

CJC-1295 No DAC is the non-DAC version of CJC-1295, representing Modified GRF (1-29) with four amino acid substitutions that provide DPP-IV resistance. Without the Drug Affinity Complex, this variant has a shorter plasma half-life, making it suitable for researchers studying pulsatile GH release patterns rather than sustained receptor activation.

Research applications include GHRH receptor pharmacology, pulsatile growth hormone release studies, GH/IGF-1 axis investigation, and comparative GHRH analog pharmacology studies contrasting the DAC and non-DAC variants. Its shorter half-life profile enables pulse-specific experimental designs.

Every batch of CJC-1295 No DAC is synthesized using Solid-Phase Peptide Synthesis (SPPS) and purified via preparative HPLC to eliminate truncated sequences and synthesis byproducts. Final identity confirmation is performed via Electrospray Ionization Mass Spectrometry (ESI-MS), verifying exact molecular weight. Each lot ships with a Certificate of Analysis documenting purity exceeding 99%, giving researchers traceable, batch-specific verification before use in any laboratory protocol.

This product is strictly for research and laboratory use only. It is not approved by the FDA or any global regulatory body for human consumption, veterinary use, or therapeutic application. The purchaser assumes all responsibility for the proper handling, storage, and application of this compound. It must only be handled by qualified professionals in a controlled laboratory setting. By purchasing this product, you agree to abide by all local and international laws regarding the use of research chemicals.